+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether antiseptic-coated sutures reduce the risk of postoperative pancreatic fistulas compared to standard sutures in patients undergoing pancreatoduodenectomy, a surgery involving removal of parts of the pancreas and nearby organs. This randomized controlled trial aims to see if using antiseptic-coated sutures can lower the rate of clinically significant fistulas within 90 days after surgery. Participants will be randomly assigned to receive either standard non-antiseptic sutures or triclosanantiseptic-coated sutures during their pancreatoduodenectomy. The antiseptic-coated sutures, specifically Ethicon PDS Plus Antibacterial Sutures, will be used at the pancreatojejunostomy layer throughout the surgery. Both sutures are commonly used at the study center. Participants will be followed for up to 90 days after surgery to monitor for postoperative pancreatic fistulas and surgical site infections. Researchers will assess outcomes such as fistula rates, infection rates, hospital and ICU length of stay, and any interventions needed for fistulas. The total participation period involves surgery and a 90-day postoperative observation to evaluate safety and effectiveness measures.

Age: 18Years +All GendersPhase Not Applicable
3 locations
R

Actively Recruiting

Researchers are evaluating how well and safely a new drug called visugromab works in people with advanced cancers that cause unintended weight loss, known as cancer-associated cachexia. This trial aims to find out if visugromab helps participants regain weight, improve appetite, and increase physical activity compared to a placebo. The study is a randomized, double-blind phase 23 trial sponsored by CatalYm GmbH. Participants receive one of several doses of visugromab or a placebo through a drip into a vein once every four weeks. The study compares low, medium, and high doses of visugromab against a placebo over the course of treatment. The main treatment period focuses on evaluating changes in body weight and appetite at 12 weeks. During the study, participants visit the hospital or clinic every four weeks for infusions and checkups. Researchers monitor medical problems, physical activity, and weight changes. The primary outcomes measured are the change in body weight and appetite after 12 weeks of treatment. The study is expected to continue through 2030, with ongoing safety and efficacy assessments throughout the participation period.

Age: 18Years +All GendersPhase 2Phase 3
79 locations